<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080104</url>
  </required_header>
  <id_info>
    <org_study_id>27-01.14-02-02</org_study_id>
    <nct_id>NCT02080104</nct_id>
  </id_info>
  <brief_title>Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery</brief_title>
  <acronym>oxytocin</acronym>
  <official_title>Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hediye Dagdeviren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour
      following vaginal delivery: A randomised controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention of postpartum haemorrhage is essential in the pursuit of improved health care for
      women. In this study investigators  aimed to compare intramuscular oxytocin with intravenous
      oxytocin for the routine prevention of postpartum haemorrhage in women who deliver
      vaginally.In some countries, intravenous access can not be provided easily . Intramuscular
      application is faster , easier and tougher enforcement requires less skill and equipment .
      For this reason, less educated , which can be applied by those offering health services .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>early postpartum hemorrhage</measure>
    <time_frame>postpartum 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood loss during the birth and postpartum hemorrhage asset (within 24 hours&gt; 500 cc blood loss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion requirement</measure>
    <time_frame>postpartum 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood transfusion requirement
duration of phase 3 (&gt; 30 min)
necessity of  additional treatments for postpartum hemorrhage
the necessity of manual removal of placenta
side effects of the</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>intravenous 10 ıu oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intramusculer 10 ıu oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group which oxytocin administered intramusculary after vaginal delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intarvenous and intramusculer 10 IU oxytocin</intervention_name>
    <description>intarvenous and intramusculer 10 IU oxytocin</description>
    <arm_group_label>intravenous 10 ıu oxytocin</arm_group_label>
    <arm_group_label>intramusculer 10 ıu oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Research volunteers, the undersigned, pregnant women

          2. Only with vaginal delivery (episiotomy and perineal tears can)

          3. &gt; 34 weeks or more will be

          4. Cephalic presentation will be

          5. At low risk of postpartum hemorrhage

        Exclusion Criteria:

          1. &lt;18 years

          2. Multiple pregnancies

          3. The presence of uterine myoma

          4. Having postpartum hemorrhage in previous pregnancies

          5. Placenta previa, polyhydramnios

          6. More than four parity

          7. Fetal macrosomia

          8. Hb &lt;9mg/dl

          9. preeclampsia

         10. Uterine anomalies

         11. Receiving anticoagulant therapy, suspected coagulopathy

         12. &gt; 42 weeks of pregnancy

         13. Oxytocin allergy -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>nurten kayacan aydemir</last_name>
    <phone>2124147171</phone>
    <phone_ext>7372</phone_ext>
    <email>nurten.aydemir@beah.gov.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bakırkoy Dr Sadi Konuk Teaching and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34140</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hediye dağdeviren , md</last_name>
      <phone>2124147171</phone>
      <phone_ext>7372</phone_ext>
      <email>hediyedagdeviren@gmail.com</email>
    </contact>
    <investigator>
      <last_name>hüseyin cengiz, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>March 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Hediye Dagdeviren</investigator_full_name>
    <investigator_title>md</investigator_title>
  </responsible_party>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>oxytocin</keyword>
  <keyword>vaginal delivery</keyword>
  <keyword>prophylactic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
